FOLLOWUS
1. Institute of Pharmacology, College of Pharmaceutical Sciences, Zhejiang Chinese Medical University,Hangzhou,China
2. Hangzhou Institute for Food and Drug Control,Hangzhou,China
3. Department of Chemistry, Zhejiang University,Hangzhou,China
纸质出版日期:2018,
网络出版日期:2018-1-15,
Scan for full text
Li, Xy., Peng, Y., Bu, Xw. et al. Balancing Effect of Biejiajian Oral Liquid (鳖甲煎口服液) on ACE-Ang II-AT1R Axis and ACE2-Ang-(1–7)-Mas Axis in Rats with CCl4-Induced Hepatic Fibrosis., Chin. J. Integr. Med. 24, 853–859 (2018). https://doi.org/10.1007/s11655-017-2909-7
Xiao-ya Li, Yan Peng, Xia-wei Bu, et al. Balancing Effect of Biejiajian Oral Liquid (鳖甲煎口服液) on ACE-Ang II-AT1R Axis and ACE2-Ang-(1–7)-Mas Axis in Rats with CCl4-Induced Hepatic Fibrosis[J]. Chinese Journal of Integrative Medicine, 2018,24(11):853-859.
Li, Xy., Peng, Y., Bu, Xw. et al. Balancing Effect of Biejiajian Oral Liquid (鳖甲煎口服液) on ACE-Ang II-AT1R Axis and ACE2-Ang-(1–7)-Mas Axis in Rats with CCl4-Induced Hepatic Fibrosis., Chin. J. Integr. Med. 24, 853–859 (2018). https://doi.org/10.1007/s11655-017-2909-7 DOI:
Xiao-ya Li, Yan Peng, Xia-wei Bu, et al. Balancing Effect of Biejiajian Oral Liquid (鳖甲煎口服液) on ACE-Ang II-AT1R Axis and ACE2-Ang-(1–7)-Mas Axis in Rats with CCl4-Induced Hepatic Fibrosis[J]. Chinese Journal of Integrative Medicine, 2018,24(11):853-859. DOI: 10.1007/s11655-017-2909-7.
To explore the effect of Biejiajian Oral Liquid (鳖甲煎口服液
BOL) on CCl4-induced hepatic fibrosis in rats by detecting the changes in the levels of angiotensin II (Ang II)
angiotensin-(1–7) [Ang-(1–7)]
angiotensin-converting enzyme (ACE)
ACE2
angiotensin II type 1 receptor (AT1R)
Mas
etc. A total of 180 Wistar rats were randomly divided into two groups by random digital table method: prevention experiment and treatment experiment. Each group was further subdivided into the following 6 subgroups: normal control group
model group
vitamin E [100 mg/(kg·d)
VE] group
enalapril [10 mg/(kg·g)
Ena] group
high-dosage [20 g/(kg·d)] BOL group
and low-dosage [10 g/(kg·d)] BOL group. The hepatic fibrosis rat model was established by subcutaneous injection of CCl4 for 6 weeks. Prevention experiment and treatment experiment were administered with specific drugs at different times. At the end of treatment experiment
the pathological changes of liver were observed after hematoxylin-eosin staining. The expressions of ingredients in renin-angiotensin-aldosterone system (RAAS) such as AngII
Ang-(1–7)
ACE
ACE2
AT1R
Mas
renin
CYP11B2 and angen in liver were detected by enzyme linked immunosorbent assay
immunohistochemistry method or reverse transcription-polymerase chain reaction
respectively. The levels of AngII and Ang-(1–7) at the 6th week increased by 496.10% and 73.64%
respectively
compared with those at the 2nd week in the model group (P<0.01). With prevention or treatment with high-dosage BOL
there was an evident reduction of AngII level but an improvement of Ang-(1–7) level. Specifically
AngII level of high-dosage group decreased by 77.50% in prevention experiment (P=0.000) and by 76.93% in treatment experiment (P=0.002) compared with that in the model group. Ang-(1–7) level increased by 91.69% in prevention experiment (P=0.006) and by 70.77% in the treatment experiment (P=0.010) compared with that in the model group. The expression levels of mRNA of renin
ACE
CYP11B2
angen and AT1R decreased by 58.15%
99.90%
99.84%
99.99% and 99.99% (all P<0.01)
respectively. BOL could help resist liver fibrosis in rats by enhancing the level of each ingredient in ACE2-Ang-(1–7)-Mas axis
while decreasing the level of each ingredient in ACE-AngII-AT1R axis. To some extent
BOL could enhance the regulation of RAAS in rats with CCl4-induced hepatic fibrosis.
To explore the effect of Biejiajian Oral Liquid (鳖甲煎口服液
BOL) on CCl4-induced hepatic fibrosis in rats by detecting the changes in the levels of angiotensin II (Ang II)
angiotensin-(1–7) [Ang-(1–7)]
angiotensin-converting enzyme (ACE)
ACE2
angiotensin II type 1 receptor (AT1R)
Mas
etc. A total of 180 Wistar rats were randomly divided into two groups by random digital table method: prevention experiment and treatment experiment. Each group was further subdivided into the following 6 subgroups: normal control group
model group
vitamin E [100 mg/(kg·d)
VE] group
enalapril [10 mg/(kg·g)
Ena] group
high-dosage [20 g/(kg·d)] BOL group
and low-dosage [10 g/(kg·d)] BOL group. The hepatic fibrosis rat model was established by subcutaneous injection of CCl4 for 6 weeks. Prevention experiment and treatment experiment were administered with specific drugs at different times. At the end of treatment experiment
the pathological changes of liver were observed after hematoxylin-eosin staining. The expressions of ingredients in renin-angiotensin-aldosterone system (RAAS) such as AngII
Ang-(1–7)
ACE
ACE2
AT1R
Mas
renin
CYP11B2 and angen in liver were detected by enzyme linked immunosorbent assay
immunohistochemistry method or reverse transcription-polymerase chain reaction
respectively. The levels of AngII and Ang-(1–7) at the 6th week increased by 496.10% and 73.64%
respectively
compared with those at the 2nd week in the model group (P<0.01). With prevention or treatment with high-dosage BOL
there was an evident reduction of AngII level but an improvement of Ang-(1–7) level. Specifically
AngII level of high-dosage group decreased by 77.50% in prevention experiment (P=0.000) and by 76.93% in treatment experiment (P=0.002) compared with that in the model group. Ang-(1–7) level increased by 91.69% in prevention experiment (P=0.006) and by 70.77% in the treatment experiment (P=0.010) compared with that in the model group. The expression levels of mRNA of renin
ACE
CYP11B2
angen and AT1R decreased by 58.15%
99.90%
99.84%
99.99% and 99.99% (all P<0.01)
respectively. BOL could help resist liver fibrosis in rats by enhancing the level of each ingredient in ACE2-Ang-(1–7)-Mas axis
while decreasing the level of each ingredient in ACE-AngII-AT1R axis. To some extent
BOL could enhance the regulation of RAAS in rats with CCl4-induced hepatic fibrosis.
Hepatic FibrosisBiejiajian Oral Liquidrenin-angiotensin-aldosterone systemcarbon tetrachlorideChinese Medicine
Hepatic FibrosisBiejiajian Oral Liquidrenin-angiotensin-aldosterone systemcarbon tetrachlorideChinese Medicine
Andrea B, Cluadia M, Alice C, Alession G, Virginia C, Francesco M, et al. Extracellular matrix molecular remodeling in human liver fibrosis evolution. PLoS One 2016;11:e0151736.
Su TH, Kao JH, Liu CJ. Molecular mechanism and treatment of viral hepatitis-related liver fibrosis. Int J Mol Sci 2014;15:10578–10604.
Ning ZW, Luo XY, Wang GZ, Li Y, Pan MX, Yang RQ, et al. MicroRNA-21 mediates angiotensin II-induced liver fibrosis by activating NLRP3 inflammasome/IL-1β axis via targeting Smad7 and Spry1. Antioxid Redox Signal 2017;27:1–20.
Drapkina OM, Drapkina IuS. Heart and liver fibrosis: the components of a single equation. Kardiologiia 2014;54:57–62.
Moreira de Macêdo S, Guimarães TA, Feltenberger JD, Sousa Santos SH. The role of renin-angiotensin system modulation on treatment and prevention of liver diseases. Peptides 2014;62:189–196.
Kim G, Kim J, Lim YL, Kim MY, Baik SK. Renin-angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review. Hepatol Int 2016;10:819–828.
Wen B, Sun H, He S, Cheng Y, Jia W, Fan E, et al. Effects of Biejiajian Pills on Wnt signal pathway signal molecules β-catenin/TCF4 complex activities and downstream proteins cyclin D1 and MMP-2 in hepatocellular carcinoma cells. J South Med Univ (Chin) 2014;34:1758–1762.
Cheng Y, He SQ, Zhu Y, Fan Q, Yang S, Chen R. Biejiajian Pill inhibited the proliferation, adhesion, and invasion of hepatoma carcinoma cells: an experimental research. Chin J Integr Tradit West Mde (Chin) 2013;33:664–667.
Sun H, He S, Wen B, Jia W, Fan E, Zheng Y. Effect of Biejiajian Pills on Wnt signal pathway molecules β-catenin and GSK-3β and the target genes CD44v6 and VEGF in hepatocellular carcinoma cells. J South Med Univ (Chin) 2014;34:1454–1458.
Ai ZB, Zhang RH, Yan GH, Su YP, Ai GP. Effect of Modified Turtle shell Decoction on hepatic fibrosis in rats and its mechanism. Acta Acad Med Milit Tertiae (Chin) 2011;33:249–254.
He S, Cheng Y, Zhu Y, Fan Q, Sun H, Jia W. Effect of Biejiajian Pills on Wnt/β-catenin signal pathway and DKK-1 and FrpHe gene expressions in hepatocellular carcinoma cells. J South Med Univ (Chin) 2013;33:30–33.
Tang YP, Hu CL, Liu YW. Effect of bioactive peptide of Carapax Trionycis on TGF-β1-induced intracellular events in hepatic stellate cells. J Ethnopharmacol 2013;148:69–73.
Hu Z, You P, Xiong S, Gao J, Tang Y, Ye X, et al. Carapax Trionycis extracts inhibit fibrogenesis of activated hepatic stellate cells via TGF-β1/Smad and NFkB signaling. Biomed Pharmacother 2017;95:11–17.
Wang P, Zhang Y, An Y, Xu K, Xu X, Fu C, et al. Protection of a new heptapeptide from Carapax trionycis against carbon tetrachloride-induced acute liver injury in mice. Chem Pharm Bull (Tokyo) 2013;61:1130–1135.
Wen B, Sun HT, He SQ, An HY, Pang J. Inhibitory effect of Biejiajian pills on HepG2 cell xenograft growth an expression of β-catenin and Tbx3 in nude mice. J South Med Univ (Chin) 2016;36:210–214.
Yao L, Yao ZM, Yu T. Influence of BOL on hyaluronic acid, laminin and hyperplasia in hepatofibrotic rats. World J Gasteroenterol 2001;7:872–875.
Yao L, Yao ZM, Weng H, Zhao GP, Zhou YJ, Yu T. Effect of rat serum containing Biejiajian Oral Liquid on proliferation of rat hepatic stellate cells. World J Gastroenterol 2004;10:1911–1913.
Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011;25:195–206.
Ghosh AK, Quaqqin SE, Vauqhan DE. Molecular basis of organ fibrosis: potential therapeutic approaches. Exp Biol Med 2013;238:461–481.
Grace JA, Herath CB, Mak KY, Burrell LM, Angus PW. Update on new aspects of the rennin-angiotensin system in liver disease: clinical implications and new therapeutic options. Clin Sci 2012;123:225–239.
Lu P, Liu HL, Yin H, Yang L. Expression of angiotensinogen during hepatic fibrogenesis and its effect on hepatic stellate cells. Med Sci Monit 2011;17: BR248–BR256.
Paik YH, Kim J, Aoyama T, De Mincicis S, Bataller R, Brenner DA. Role of NADPH oxidases in liver fibrosis. Antioxid Redox Signal 2014;20:2854–2872.
Yao ZM, Xiong YK, Li JP. Experimental study of resisting liver fibrosis of Biejiajian Oral Liquid. J Zhejiang Univ Tradit Chin Med (Chin) 2000;24:58–61.
Yao L, Zhang YL, Li J, Peng Y. Effect of Biejiajian Oral Liquid on the expression of RAAS in hepatic fibrosis rats. J Pharm Pharmacol 2012;3:330–335.
0
浏览量
0
Downloads
3
CSCD
关联资源
相关文章
相关作者
相关机构